Compare ACADIA Pharmaceuticals Inc. (ACAD) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs FedEx Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.37 (market cap $5.07B), while FedEx Corporation trades at $324.47 (market cap $76.28B). The key difference: FedEx Corporation is far larger — about 15× ACADIA Pharmaceuticals Inc.'s market cap, and FedEx Corporation pays a 1.51% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | FDX | |
|---|---|---|
Market Cap | $5.07B | $76.28B |
Sector | Health | Industrials |
52-Week High | $29.41 | $338.75 |
52-Week Low | $20.06 | $180.51 |
Enterprise Value | $4.19B | $105.91B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
FedEx (FDX) trades at $325.08, up 2.04% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a consensus price target of $360.27 highlight positive momentum. The company's network transformation and focus on premium shipments are driving operational improvements, though revenue has been flat year-over-year. Cash flow trends show a projected rebound in 2026, with net cash flow turning positive.
The outlook for FDX is favorable, supported by cost-cutting initiatives and strategic shifts toward high-margin business. Key risks include competitive pressures and macroeconomic sensitivity. With 57% of analysts rating it a buy and institutional interest growing, the stock presents a compelling opportunity for growth-oriented investors, albeit with exposure to economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
